3 U.S. lawmakers have disclosed 6 Takeda Pharmaceutical Company Limited American Depositary Shares trades under the STOCK Act — 5 buys and 1 sell between 2018 and 2026. Congress has been net buyers of TAK, and their disclosed buys are down 4.8% versus the latest close.
*Notional-weighted price return on lawmakers' disclosed buys of TAK, marked to the latest close — per-share (share counts aren't disclosed).
| Date | Member | Type | Amount | Est. price | Latest close | Return |
|---|---|---|---|---|---|---|
| 2026-03-30 | Alan Armstrong | BUY | $1K–$15K | $18.27 | $17.39 2026-08-13 | -4.8% |
| 2023-08-29 | Virginia Foxx | SELL | $15K–$50K | $15.35 | $17.39 2026-08-13 | +15.6% rt |
| 2023-02-16 | Virginia Foxx | BUY | $1K–$15K | $15.56 | $17.39 2026-08-13 | +11.8% |
| 2022-11-01 | Virginia Foxx | BUY | $1K–$15K | $13.28 | $17.39 2026-08-13 | +30.9% |
| 2018-01-04 | David P. Roe | BUY | $1K–$15K | $29.01 | $17.39 2026-08-13 | -40.1% |
| David P. Roe | BUY | $1K–$15K | — | — | — |
Return: buys marked to the latest close (open); sells tagged rt are realized round-trips vs a prior disclosed buy; exit = timing (stock move after the sale, seller's perspective).
3 members of the U.S. House and Senate have disclosed Takeda Pharmaceutical Company Limited American Depositary Shares transactions under the STOCK Act — 5 purchases and 1 sale. The full member-by-member breakdown, with dates and dollar ranges, is in the table above.
No member of Congress has disclosed a TAK purchase in the last 90 days. STOCK Act filings lag the trade by up to 45 days, so newer buys may still be pending disclosure.
Notional-weighted, lawmakers' disclosed TAK buys are down 4.8% versus the latest close of $17.39. Each trade's own return — and realized round-trips on matched sells — is in the Return column.
Yes. Under the 2012 STOCK Act, members of Congress may buy and sell individual stocks but must publicly disclose each transaction within 45 days. Bargo surfaces those filings so you can see who traded TAK and how it performed.